Home › NDC Lookup › RxCUI directory › RxCUI 1310531

Teriflunomide 14 MG Oral Tablet [Aubagio] — RxCUI 1310531

RxNorm drug concept · Semantic branded drug
RxCUI 1310531 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1310531
Official nameTeriflunomide 14 MG Oral Tablet [Aubagio]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAubagio 14 MG Oral Tablet
FDA products mapped2
Package NDCs mapped6
Reported Medicaid activity (SDUD)785 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Teriflunomide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats relapsing forms of multiple sclerosis in adults. That includes a first episode of MS-like symptoms, relapsing-remitting MS, and active secondary progressive MS. It's sold...
  • Take one tablet by mouth once a day. You can take it with or without food. Follow your prescriber's directions and your pharmacy label for the exact dose.
  • The most common are headache, diarrhea, nausea, hair thinning, tingling or numbness, and joint pain. Your liver enzymes may also rise on blood tests. Call your doctor if you notice...
  • Teriflunomide can injure the liver and lower your white blood cells. Your liver tests are checked before you start and at least monthly for six months. A blood count, tuberculosis...
📖 Read our full Teriflunomide guide →

🕸️ Concept Web — How Teriflunomide 14 MG Oral Tablet [Aubagio] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Teriflunomide 14 MG Oral Tablet [Aubagio] RxCUI 1310531

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Teriflunomide 1310520
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aubagio 1310526
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Teriflunomide Oral Tablet 1310524
    • Teriflunomide Oral Product 1310522
    • Teriflunomide Pill 1310523
    • Teriflunomide Oral Tablet [Aubagio] 1310528
    • Aubagio Oral Product 1310529
    • Aubagio Pill 1310530
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Teriflunomide 14 MG Oral Tablet SCD · 1310525
  • Teriflunomide 14 MG SCDC · 1310521
  • Teriflunomide Oral Tablet SCDF · 1310524
  • Teriflunomide Oral Product SCDG · 1310522
  • Teriflunomide Pill SCDG · 1310523

Brand-Name Concepts

  • Teriflunomide 14 MG [Aubagio] SBDC · 1310527
  • Teriflunomide Oral Tablet [Aubagio] SBDF · 1310528
  • Aubagio Oral Product SBDG · 1310529
  • Aubagio Pill SBDG · 1310530
  • Aubagio BN · 1310526

📦 FDA Products & Package NDCs

2 products · 6 package NDCs
6 package NDCs map to RxCUI 1310531 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
58468-0210-01 1 BLISTER PACK in 1 CARTON (58468-0210-1) / 5 TABLET, FILM... Aubagio Genzyme Corporation 2013-05-01
58468-0210-03 1 BLISTER PACK in 1 CARTON (58468-0210-3) / 5 TABLET, FILM... Aubagio Genzyme Corporation 2013-05-01
58468-0210-04 1 BOTTLE in 1 CARTON (58468-0210-4) / 30 TABLET, FILM COATE... Aubagio Genzyme Corporation 2019-03-28
58468-0211-02 1 BLISTER PACK in 1 CARTON (58468-0211-2) / 5 TABLET, FILM... Aubagio Genzyme Corporation 2013-05-01
58468-0211-03 1 BLISTER PACK in 1 CARTON (58468-0211-3) / 5 TABLET, FILM... Aubagio Genzyme Corporation 2013-05-01
58468-0211-04 1 BOTTLE in 1 CARTON (58468-0211-4) / 30 TABLET, FILM COATE... Aubagio Genzyme Corporation 2019-03-28
Observed labelers: Genzyme Corporation (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.